Venus Remedies Secures Kenyan GMP Certification for All Its Manufacturing Facilities in Baddi
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans Venus Remedies Limited, a leading research-based pharmaceutical company, has achieved another significant
- The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans
Venus Remedies Limited, a leading research-based pharmaceutical company, has achieved another significant milestone by securing a Good Manufacturing Practices (GMP) certification from Kenya for all its production facilities in Baddi. Acknowledging the commitment of Venus Remedies to quality assurance and international manufacturing standards, the Pharmacy and Poisons Board (PPB) of the Kenyan Health Ministry granted the certification following a rigorous audit of the company’s production facilities in Baddi.
With this, the number of international GMP certifications for Venus Remedies has gone up to 25.
This recognition, a testament to Venus Remedies’ commitment to delivering safe and effective drugs of the highest quality to patients worldwide, encompasses a wide range of parenteral formulations, including pre-filled syringes, ampoules, vial liquids and lyophilised and dry powder injections. Notably, the GMP certification extends to the manufacturing facilities for cephalosporins and carbapenems as dry powder injections, oral granules and liquid and lyophilised oncology products.
Hailing this achievement, Saransh Chaudhary, President, Global Critical Care, Venus Remedies Ltd, said, “This GMP certification validates our relentless pursuit of excellence and further strengthens our position as a leading manufacturer of fixed-dosage injectables. It paves the way for consolidating our position in Kenya and other African markets as part of our global expansion plans.”
The GMP from Kenya, estimated to be a $780 million market, is set to bolster the expansion of Venus Remedies in the COSMEA (Common Market for Eastern and Southern Africa) region, of which Kenya is a key member, and subsequently the entire African pharmaceutical market, which is estimated to be worth $7.3-billion. The company has a presence in Uganda, Tanzania, Kenya and Rwanda countries in Africa, where the pharmaceutical market is expected to grow upto $2.8 billion by year 2023 at a CAGR of 10% approx.
Akshansh Chaudhary, Executive Director, Venus Remedies, said the company will leverage this certification to bring it diverse range of high-quality products to the Kenyan and other African markets, thus making a positive impact on healthcare in the region. “This achievement is aligned with our vision of improving global health and reinforces our commitment to delivering excellence in pharmaceutical manufacturing,” he said.
The GMP certification awarded by Kenya comes just three months after the company secured a GMP approval from Saudi Arabia, which is expected to speed up the process of marketing authorisations for the company’s products in Gulf Cooperation Council (GCC) and Middle East and North Africa (MENA) regions.